Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAXINIA in Metastatic or Advanced Solid Tumors
NCT05346484Phase 1Terminated
- Sponsor
- Imugene
- Start
- May 2022
- Primary completion
- Jan 2026
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label trial of Vaxinia in solid tumor and cholangiocarcinoma (CCA), sponsored by Imugene. Primary endpoints: Frequency and severity of Adverse Events and Recommended Phase 2 Dose. Started May 2022; status: terminated.
02
Drugs
Vaxinia
03
Conditions
solid tumorcholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05346484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346484.